|Mr. Steven E. Hoffman||Co-Founder, Chairman, CEO & Chief Science Officer||900.44k||N/A||1963|
|Mr. Ben R. Taylor||Pres & CFO||623.29k||N/A||1977|
|Mr. James Biehl J.D.||Chief Legal Officer & Sec.||730.78k||N/A||1964|
|Ms. Michele Ilene Korfin||Chief Operating Officer||N/A||N/A||1972|
|Ms. Barbara C. Galaini||Principal Accounting Officer & Corp. Controller||N/A||N/A||1958|
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in Phase II clinical trials to treat cancer, including pancreatic, lung, breast, prostate, and sarcoma cancers. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Tyme Technologies, Inc.’s ISS Governance QualityScore as of December 4, 2019 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 4; Compensation: 8.